OneCell Diagnostics Secures $16M Series A to Advance AI Cancer Treatment

OneCell Diagnostics lands $16M Series A funding to revolutionize cancer treatment with AI-driven precision. By targeting cancer recurrence, the startup’s groundbreaking technology offers a diagnosis 100 times more informative than current methods, paving the way for enhanced patient outcomes globally.

In a groundbreaking advancement that could redefine cancer treatment, OneCell Diagnostics has recently secured $16 million in a Series A funding round.

This promising genomics-based startup is on a mission to limit cancer recurrence using cutting-edge AI technology and scientific innovation.

As the global cancer burden is projected to skyrocket, with the World Health Organization estimating over 35 million cases by 2050, OneCell’s pioneering approach could be a game-changer in the fight against this formidable disease.

Founded in 2021, OneCell Diagnostics has already made significant strides in India, serving nearly 10,000 patients with its innovative blood-based biopsy testing.

Unlike traditional cancer detection methods like PET CT scans and MRIs, OneCell’s proprietary technology focuses on detecting circulating tumor cells (CTCs) from a simple 10ml blood draw.

This approach, termed True-Single-Cell-Multi-omics, combines AI with sophisticated scientific methods to offer a diagnosis with 100 times more information than current liquid biopsy tests.

The technology captures and isolates CTCs using a unique glass bead with antibodies specifically targeting cancer cells.

The startup’s app, iCare, is another leap forward in precision oncology.

By utilizing AI and machine learning, iCare empowers oncologists to interpret complex test reports, bridging the gap between medical knowledge and the intricate science of cell analysis.

“It’s the innovation at the intersection of very deep science, the cell science, and data science, that is a perfect storm,” says Mohan Uttarwar, co-founder and CEO of OneCell.

His vision is for every oncologist worldwide to adopt precision oncology, enhancing their ability to tailor treatments to individual patient needs.

Despite its revolutionary potential, OneCell is strategically avoiding the high-risk area of first-time cancer patients due to regulatory hurdles in the U.S., choosing instead to focus on the reoccurrence patient market.

This move positions OneCell distinctively against competitors like Guardant Health and Natera, offering diagnosis precision at a fraction of the cost.

The startup operates under a B2B2C model, providing its biopsy tests through partnerships with hospitals and oncologists.

Its operations span from Mumbai to Silicon Valley, with plans to expand in the U.S. market soon.

With strategic alliances with top-tier institutions such as Harvard Medical School and Stanford University, OneCell has amassed substantial data to refine its AI systems and strengthen its analytical capabilities.

The recent funding round, led by Celesta Capital and supported by Tenacity Ventures, Cedars Sinai, and others, will fuel OneCell’s expansion efforts in the U.S. and further growth in India.

Notably, the addition of Nobel Laureate James Rothman to its board underscores the scientific credibility and ambitious trajectory of the startup.

As the world grapples with the rising tide of cancer cases, OneCell Diagnostics stands as a beacon of hope.

By leveraging the power of AI and precision science, it is poised to transform cancer recurrence management, potentially improving outcomes for millions of patients worldwide.

With its innovative approach and strategic foresight, OneCell is not just participating in the fight against cancer—it’s leading it.